Forte Biosciences, Inc. (FBRX)

NASDAQ: FBRX · IEX Real-Time Price · USD
0.723
+0.008 (1.08%)
At close: Apr 12, 2024, 3:59 PM
0.700
-0.023 (-3.21%)
After-hours: Apr 12, 2024, 4:00 PM EDT
1.08%
Market Cap 26.32M
Revenue (ttm) n/a
Net Income (ttm) -31.48M
Shares Out 36.39M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,093
Open 0.720
Previous Close 0.716
Day's Range 0.700 - 0.723
52-Week Range 0.380 - 1.150
Beta 1.65
Analysts Strong Buy
Price Target 2.75 (+280.2%)
Earnings Date May 13, 2024

About FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Paul A. Wagner Ph.D.
Employees 9
Stock Exchange NASDAQ
Ticker Symbol FBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for FBRX stock is "Strong Buy" and the 12-month stock price forecast is $2.75.

Price Target
$2.75
(280.20% upside)
Analyst Consensus: Strong Buy

News

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...

25 days ago - Business Wire

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement aw...

4 months ago - Business Wire

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2...

5 months ago - Business Wire

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” ...

7 months ago - Business Wire

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” ...

7 months ago - Business Wire

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” ...

8 months ago - Business Wire

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter...

8 months ago - Business Wire

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced key R&D updates for FB-102 and the clo...

9 months ago - Business Wire

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provide...

11 months ago - Business Wire

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a ...

1 year ago - Business Wire

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.

1 year ago - Business Wire

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provi...

1 year ago - Business Wire

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.

1 year ago - Business Wire

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Comp...

1 year ago - Business Wire

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provid...

1 year ago - Business Wire

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement aw...

2 years ago - Business Wire

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the compa...

2 years ago - Business Wire

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provide...

2 years ago - Business Wire

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.

2 years ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ...

2 years ago - Newsfile Corp

Why Forte Biosciences Stock Is Down Over 80% Today

Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are appre...

2 years ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).

2 years ago - PRNewsWire

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

The negative drug results led Chardan Capital Markets to slash its price target by 96% to $4 from $105.

2 years ago - Business Insider

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its le...

2 years ago - Market Watch

Forte Biosciences Just Plummeted 80%: Here's Why

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug ...

2 years ago - Benzinga